Skip to main content
Premium Trial:

Request an Annual Quote

Centogene, Denali Therapeutics Partner to Recruit Parkinson's Patients for Drug Program

NEW YORK (GenomeWeb) – German diagnostics firm Centogene said today that it has entered into an agreement with Denali Therapeutics to conduct a targeted global patient identification and recruitment campaign for the company's Parkinson's disease LRRK2 inhibitor program.

Centogene will use its CentoCard, a proprietary dried blood spot collection kit, to collect samples that can identify Parkinson's patients who carry mutations in the LRRK2 gene. According to the company, these mutations are one of the most commonly known genetic causes of Parkinson's disease, driving lysosomal dysfunction, which contributes to the formation of Lewy body protein aggregates and neurodegeneration.

The arrangement is not Centogene's first in the area of Parkinson's disease. The firm has also been collaborating with the Parkinson's Institute to use a large gene panel to screen patients for genetic variants associated with the disease.

Carole Ho, chief medical officer and head of development at Denali, said in a statement that the company's trials are the first to apply LRRK2 inhibitors in the treatment of Parkinson's.

"This partnership with Centogene is a central part of our global efforts to identify and recruit PD patients with a mutation in the LRRK2 gene into our planned clinical studies," she added.

Financial terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.